Dr. D. Ross Camidge
Oxford University, Oxford, UK - 1988
Oxford University Medical School, Oxford, UK - 1995
John Radcliffe Hospital, Oxford, UK - 1995
Dr. D. Ross Camidge is an associate professor in the division of medical oncology and serves as both the director of the thoracic oncology clinical program and the program director for the thoracic oncology clinical and translational research fellowship at the University of Colorado School of Medicine. Dr. Camidge joined the University of Colorado as a full-time faculty member in October of 2007 after having served as a visiting professor at the university for two years prior. Dr. Camidge has been described by the Bonnie J. Addario Lung Cancer Foundation as “one of the leading minds in lung cancer.”
Dr. D. Ross Camidge earned his BA in 1988 from Oxford University located in Oxford, United Kingdom and his PhD in 1992 from Cambridge University located in Cambridge, United Kingdom. He then went on to pursue his medical degree at Oxford University Medical School where he graduated in 1995. He completed his internship at John Radcliffe Hospital in Oxford that same year. Dr. Camidge is trained in both medical oncology and clinical pharmacology.
Clinical and Laboratory Research
Dr. Camidge’s clinical interests consist primarily of thoracic malignancies—namely lung cancer, thymic cancers, and mesothelioma—and oncology drug development. He is an advocate for lung cancer patients attaining the latest drugs available via clinical trials and much of his research focuses on the optimization of new agents by means of personalized medicine—identifying the mechanisms “driving” a cancer and then tailoring the drug therapy to that specific cancer’s genetic makeup.
Dr. Camidge has a particular interest in developmental therapeutics—phase I studies. He serves as the principal investigator on numerous trials, both on the national and international level, that are funded either directly by the pharmaceutical industry or through industry-related grants. Dr. Camidge has authored or co-authored over 100 articles published in well-respected, peer-reviewed, scientific journals.
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Kris MG, Camidge DR, Giaccone G, Hida T, Li BT, O'Connell J, Taylor I, Zhang H, Arcila ME, Goldberg Z, Jänne PA. Ann Oncol. 2015 Apr 21. [Epub ahead of print].
Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? Does targeted therapy make patients live longer? Hard to prove, but impossible to ignore. Camidge DR. Clin Adv Hematol Oncol. 2014 Nov;12(11):763-6.
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D, Alexandris E, Yurasov S, Camidge DR, Bonomi P. Cancer. 2015 Mar 15;121(6):883-92. Epub 2014 Nov 6.
Acquired resistance to TKIs in solid tumours: learning from lung cancer. Camidge DR, Pao W, Sequist LV. Nat Rev Clin Oncol. 2014 Aug;11(8):473-81. Epub 2014 Jul 1. Review.
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study. Blais N, Camidge DR, Jonker DJ, Soulières D, Laurie SA, Diab SG, Ruiz-Garcia A, Thall A, Zhang K, Chao RC, Chow LQ. Invest New Drugs. 2013 Dec;31(6):1487-98. Epub 2013 Aug 22.
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Camidge DR, Blais N, Jonker DJ, Soulières D, Doebele RC, Ruiz-Garcia A, Thall A, Zhang K, Laurie SA, Chao RC, Chow LQ. Cancer Chemother Pharmacol. 2013 Feb;71(2):307-19. Epub 2012 Oct 30.Sources
University of Colorado Cancer Center